Best eQMS for FDA QMSR — the 2026 Transition Guide

The FDA Quality Management System Regulation (QMSR) is the final rule that replaced 21 CFR Part 820 effective 2026-02-02. It harmonises FDA’s quality system requirements for medical device manufacturers with ISO 13485:2016, while retaining FDA-specific provisions on labelling, UDI, complaint handling, and Medical Device Reporting (MDR). The QMSR applies to all medical devices marketed in the US.

Part 820 was a US-specific regulation built independently from ISO 13485, leading to duplicate quality systems for manufacturers selling globally. The QMSR incorporates ISO 13485:2016 by reference and overlays FDA-specific provisions where ISO 13485 is silent (e.g. UDI under §830, complaint handling, MDR reporting under §803). For most manufacturers already certified to ISO 13485, the QMSR transition is incremental — verify FDA-specific overlays are documented in your QMS.

No. eQMS platforms aligned to ISO 13485 + Part 820 generally remain valid under QMSR. The transition is procedural rather than technological: update SOPs to reference QMSR (instead of Part 820), re-train staff, and ensure FDA-specific overlays (UDI, MDR reporting, complaint handling) are evidenced. Verify your vendor’s QMSR alignment statement and confirm the validation pack references the QMSR sub-clauses where Part 820 was previously cited.

The QMSR retains Design Controls requirements (Class II and Class III devices) by incorporating ISO 13485 §7.3 (Design and Development) and adding FDA-specific clarifications. The Design History File (DHF) — design inputs, outputs, reviews, V&V, transfer, changes — remains required and must be maintained for the lifetime of the device plus 2 years. eQMS platforms support DHF either as a first-class Design Controls module or through linked records across Documents, Risk, Change, and CAPA.

No fundamental change. UDI requirements under 21 CFR Part 830 remain in force unchanged. MDR (adverse event reporting) under 21 CFR Part 803 remains unchanged. The QMSR clarifies how these FDA-specific obligations sit alongside ISO 13485-aligned QMS processes. The eQMS must support UDI tracking on device records, MDR workflow with FDA reporting timelines (5 / 30 day windows), and traceable linkages between complaints, MDR reports, and CAPA.

The FDA QMSR final rule was published 2024-01-31 (89 FR 7496) with a 2-year transition period. The QMSR became effective 2026-02-02. As of that date, 21 CFR Part 820 references in regulatory submissions and inspection findings transition to the QMSR. Quality system documentation should be updated to cite the QMSR going forward; legacy records citing Part 820 remain valid for their original retention period.

QMSR (via ISO 13485 §8.2.2 + FDA overlays) requires a documented complaint handling procedure: complaint receipt, evaluation for MDR reportability, investigation, root cause analysis, CAPA linkage, response to complainant, and trending. The eQMS Events / Complaints module must support each step with audit trail, evaluator roles, MDR reportability decision logging, time-bound investigation workflow, CAPA linkage, and trending dashboards. Complere covers all of this in the Events module with linked CAPA workflow.

QMSR’s harmonisation with ISO 13485 reduces the gap with EU MDR (which also references ISO 13485 for QMS) and other ISO 13485-aligned regulations (Health Canada CMDR, Japan MHLW, ANVISA Brazil, TGA Australia). A single ISO 13485-aligned QMS now serves more jurisdictions with FDA-specific overlays as needed. Multi-vertical eQMS platforms with regional residency (Complere) are well-positioned for global manufacturers managing both QMSR and EU MDR simultaneously.

Validation evidence (URS, IQ, OQ, PQ, Part 11 checklist, ATS) generated under Part 820 remains valid as historical records. Going forward, new validation activities should reference the QMSR sub-clauses (which alias to Part 820 + ISO 13485). Most eQMS validation packs alias their requirement traceability to both Part 820 and ISO 13485 — re-aliasing to QMSR is a documentation update, not a re-validation. Verify your vendor regenerates the validation pack under QMSR going forward.

Ask each vendor for: (1) a written QMSR alignment statement covering ISO 13485:2016 + FDA-specific overlays (UDI, MDR, complaint handling); (2) the validation pack with QMSR sub-clause traceability; (3) Design Controls / DHF support model (first-class module vs linked records); (4) record retention configuration matching the QMSR’s lifetime + 2-year requirement; (5) a roadmap for QMSR-driven feature updates. Compare against the same 14-criteria scoring matrix used for general eQMS evaluation, with QMSR-specific overlays as additional rows.